Healthcare provider profile · identity verified

Isaac Chitrit, MD

Internal Medicine · SUNSET VALLEY, TX · NPI 1144200403

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	552	194
Lisinopril	Lisinopril	324	118
Amlodipine Besylate	Amlodipine Besylate	313	120
Levothyroxine Sodium	Levothyroxine Sodium	247	79
Metformin Hcl	Metformin Hcl	200	72
Pravastatin Sodium	Pravastatin Sodium	172	72
Gabapentin	Gabapentin	162	58
Albuterol Sulfate Hfa	Albuterol Sulfate	151	42
Rosuvastatin Calcium	Rosuvastatin Calcium	151	63
Losartan Potassium	Losartan Potassium	146	60
Pantoprazole Sodium	Pantoprazole Sodium	127	49
Metoprolol Succinate	Metoprolol Succinate	122	45
Hydrochlorothiazide	Hydrochlorothiazide	114	40
Famotidine	Famotidine	113	36
Tamsulosin Hcl	Tamsulosin Hcl	111	44
Omeprazole	Omeprazole	101	40
Glipizide	Glipizide	98	38
Carvedilol	Carvedilol	97	36
Fluticasone Propionate	Fluticasone Propionate	97	41
Furosemide	Furosemide	92	37
Metformin Hcl Er	Metformin Hcl	85	37
Pioglitazone Hcl	Pioglitazone Hcl	85	26
Tizanidine Hcl	Tizanidine Hcl	81	30
Trazodone Hcl	Trazodone Hcl	73	21
Simvastatin	Simvastatin	60	26
Alendronate Sodium	Alendronate Sodium	57	21
Metoprolol Tartrate	Metoprolol Tartrate	57	23
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	55	20
Clopidogrel	Clopidogrel Bisulfate	47	21
Potassium Chloride	Potassium Chloride	47	15
Eliquis	Apixaban	46	15
Jardiance	Empagliflozin	45	16
Montelukast Sodium	Montelukast Sodium	45	14
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	45	16
Duloxetine Hcl	Duloxetine Hcl	44	13
Escitalopram Oxalate	Escitalopram Oxalate	44	12
Ozempic	Semaglutide	43	13
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	42	17
Sertraline Hcl	Sertraline Hcl	42	18
Doxycycline Monohydrate	Doxycycline Monohydrate	40	26
Fluoxetine Hcl	Fluoxetine Hcl	40	suppressed
Januvia	Sitagliptin Phosphate	39	13
Chlorthalidone	Chlorthalidone	36	13
Rybelsus	Semaglutide	35	suppressed
Ezetimibe	Ezetimibe	33	15
Lantus	Insulin Glargine,hum.Rec.Anlog	33	suppressed
Meloxicam	Meloxicam	33	18
Memantine Hcl	Memantine Hcl	33	14
Allopurinol	Allopurinol	32	15
Glipizide Er	Glipizide	31	11
Xarelto	Rivaroxaban	31	suppressed
Meclizine Hcl	Meclizine Hcl	30	12
Zolpidem Tartrate	Zolpidem Tartrate	30	suppressed
Celecoxib	Celecoxib	28	17
Oxybutynin Chloride Er	Oxybutynin Chloride	28	suppressed
Cephalexin	Cephalexin	27	21
Glimepiride	Glimepiride	27	13
Irbesartan	Irbesartan	27	11
Alprazolam	Alprazolam	26	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	26	12
Azithromycin	Azithromycin	25	25
Clonidine Hcl	Clonidine Hcl	25	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	25	suppressed
Gentamicin Sulfate	Gentamicin Sulfate	25	15
Hydralazine Hcl	Hydralazine Hcl	25	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	24	suppressed
Buspirone Hcl	Buspirone Hcl	23	suppressed
Incontrol Pen Needle	Pen Needle, Diabetic	23	suppressed
Linzess	Linaclotide	23	suppressed
Donepezil Hcl	Donepezil Hcl	22	11
Ondansetron Hcl	Ondansetron Hcl	22	suppressed
Benazepril Hcl	Benazepril Hcl	21	suppressed
Citalopram Hbr	Citalopram Hydrobromide	21	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	21	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	21	suppressed
Trulicity	Dulaglutide	21	suppressed
Lorazepam	Lorazepam	20	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	19	suppressed
Atenolol	Atenolol	19	suppressed
Finasteride	Finasteride	19	suppressed
Methocarbamol	Methocarbamol	19	suppressed
Nystatin	Nystatin	19	suppressed
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Tramadol Hcl	Tramadol Hcl	19	suppressed
Valsartan	Valsartan	19	suppressed
Levemir Flexpen	Insulin Detemir	18	suppressed
Pregabalin	Pregabalin	18	suppressed
Torsemide	Torsemide	18	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	18	suppressed
Nystop	Nystatin	17	suppressed
Ondansetron Odt	Ondansetron	17	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Tresiba Flextouch U-100	Insulin Degludec	16	suppressed
Mirtazapine	Mirtazapine	15	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	15	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	15	suppressed
Amoxicillin	Amoxicillin	14	13
Enalapril Maleate	Enalapril Maleate	14	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	14	suppressed
Ibuprofen	Ibuprofen	14	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	14	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	14	suppressed
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Bupropion Xl	Bupropion Hcl	13	suppressed
Spironolactone	Spironolactone	13	suppressed
Ulticare Pen Needle	Pen Needle, Diabetic	13	suppressed
Diltiazem 24hr Er (Xr)	Diltiazem Hcl	12	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	12	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	12	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Alcohol Pads	Alcohol Antiseptic Pads	11	suppressed
Dexlansoprazole Dr	Dexlansoprazole	11	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed
Humalog Kwikpen U-200	Insulin Lispro	11	suppressed
Probenecid-Colchicine	Probenecid/Colchicine	11	suppressed
Spiriva Handihaler	Tiotropium Bromide	11	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error